HEART-LUNG TRANSPLANTATION - SUCCESSFUL THERAPY FOR PATIENTS WITH PULMONARY VASCULAR-DISEASE
HEART-LUNG TRANSPLANTATION - SUCCESSFUL THERAPY FOR PATIENTS WITH PULMONARY VASCULAR-DISEASE
复制标题
DOI：
10.1056/nejm198203113061001
复制
发表时间：
1982-01-01
影响因子：
158.5
通讯作者：
SHUMWAY, NE
中科院分区：
文献类型：
--
作者：
REITZ, BA;WALLWORK, JL;SHUMWAY, NE
本文报告三例心肺联合移植患者。主要使用的免疫抑制剂是环孢菌素A，尽管也使用常规药物。第1例患者为45岁女性，患有原发性肺动脉高压，术后10天和25天诊断为移植急性排斥反应，但成功治疗;该患者10个月后仍具有正常的运动耐量。后第2例患者为30岁男性，因房和室间隔缺损导致的艾森门格综合征接受移植。移植物无排斥反应，8个月后病情明显好转。手术后。第3例患者为一名29岁女性，患有大血管转位和相关缺陷，术后4天死于肾、肝和肺并发症。成功是由于灵长类动物心肺移植的经验，环孢菌素A的使用和联合心肺置换的解剖和生理优势。希望这种移植可以为肺血管疾病和某些其他顽固性心肺疾病的晚期患者提供更好的前景。
Three patients who received heart-lung transplants are reported. The primary immunosuppressive agent used was cyclosporin A, although conventional drugs were also administered. In the 1st patient, a 45-yr-old woman with primary pulmonary hypertension, acute rejection of the transplant was diagnosed 10 and 25 days after surgery but was treated successfully; this patient still had normal exercise tolerance 10 mo. later. The 2nd patient, a 30-yr-old man, underwent transplantation for Eisenmenger''s syndrome due to atrial and ventricular septal defects. His graft was not rejected, and his condition was markedly improved 8 mo. after surgery. The 3rd patient, a 29-yr-old woman with transposition of the great vessels and associated defects, died 4 days postoperatively of renal, hepatic and pulmonary complications. Success was due to experience with heart-lung transplantation in primates, to the use of cyclosporin A and to the anatomic and physiologic advantages of combined heart-lung replacement. Hopefully, such transplants may provide an improved outlook for selected terminally ill patients with pulmonary vascular disease and certain other intractable cardiopulmonary disorders.